Chemotherapy

Erbitux for Squamous Cell Cancer of Unknown Primary Site – pro

When the primary site is not identified and when it does not fall neatly into certain specific clinical patterns, empiric broad-spectrum chemotherapy is recommended by NCCN and is generally acceptable. The issue remains second line chemotherapy. Erbitux is approved for squamous cell cacner of head and neck and is an attractive candidate for unknown primary. Unfortunately, these patients have a dismal prognosis despite management with a variety of

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39